COEP Coeptis Therapeutics Holdings Inc
2,204
$0.3501
$0.0052
(1.46%)
| Watchers | 2,204 |
| 52-Wk Low | $0.2851 |
| 52-Wk High | $2.19 |
| Market Cap | $13M |
| Volume | 34,592.00 |
| 52-Wk High | $2.19 |
| 52-Wk Low | $0.2851 |
Coeptis Therapeutics to Present its Universal Allogeneic SNAP-CAR NK Cell Therapy at the ISCT 2024PR Newswire • 11 days ago
Coeptis Therapeutics to Present its Universal Allogeneic SNAP-CAR NK Cell Therapy at the ISCT 2024 Coeptis Therapeutics to Present its Universal Allogeneic SNAP-CAR NK Cell Therapy at the ISCT 2024...
Share to Feed
Coeptis Therapeutics Announces Poster Data Presentation at American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting Coeptis Therapeutics Announces Poster Data Presentation at American...
Coeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on Receiving the 2024 Chancellor's Distinguished Research Award Coeptis Therapeutics Congratulates...
Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK Coeptis Therapeutics Adds Autoimmune Indications to...
Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral Infections Coeptis Therapeutics to Pursue Phase 2 Program Using...
Coeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024 Coeptis Therapeutics President and CEO Issues Letter to Shareholders...